Table 3.
Overview of results of the biomarker screening. Data for the percentage of tumours expressing each marker as well as the percentage of tumours showing inactivating genetic variants are shown.
| BRAF | 0% | 0% | 11% | 6% | ||||
|---|---|---|---|---|---|---|---|---|
| EGFR | 88% | 6% | 100% | 12% | 56% | 6% | 60% | 18% |
| ERBB2 | 12% | 12% | 16% | 24% | ||||
| FAS | 63% | 23% | 31% | 20% | ||||
| FGFR1 | 100% | 0% | 92% | 6% | 63% | 5% | 80% | 0% |
| FIGF | 38% | 0% | 31% | 7% | ||||
| FLT4 | 69% | 38% | 13% | 20% | ||||
| HRAS | 0% | 0% | 0% | 0% | ||||
| IGF1 | 88% | 38% | 56% | 53% | ||||
| IGF2 | 88% | 85% | 56% | 87% | ||||
| KDR | 69% | 0% | 54% | 6% | 31% | 0% | 40% | 0% |
| KIT | 0% | 12% | 0% | 0% | ||||
| KRAS | 0% | 6% | 11% | 0% | ||||
| MDM2 | 81% | 77% | 50% | 93% | ||||
| MET | 69% | 0% | 62% | 12% | 31% | 5% | 60% | 0% |
| MTOR | 81% | 100% | 44% | 80% | ||||
| NOTCH1 | 0% | 0% | 0% | 0% | ||||
| NRAS | 0% | 0% | 0% | 6% | ||||
| PIK3CA | 0% | 6% | 0% | 24% | ||||
| RET | 6% | 6% | 5% | 18% | ||||
| TP53 | 0% | 0% | 63% | 65% |